Investigational treatments for lung cancer, Huntington’s disease and Alzheimer's gain Innovation Passports through the Innovative Licensing and Access Pathway 

Imported from official source

Alert

Safety Classified by Officially

This means they can access coordinated support throughout development through the UK’s Innovative Licensing and Access Pathway (ILAP). This is the only end-to-end access pathway in the world where developers can work, from early stages of clinical development, with the national health system, the regulator and health technology assessment bodies. 

The ILAP is designed to de-risk product development and accelerate patient access to transformative new medicines and drug-device combinations, by providing a single integrated platform for collaboration. 

Following assessment by the ILAP Selection Panel, Innovation Passports have been awarded to:  

A chemical siRNA (small interfering RNA that can silence genes by cleaving mRNA) for the treatment of Huntington’s disease  

A chemical small molecule oncology therapy, with first-line Non-Small Cell Lung Cancer (NSCLC) expected to be the lead indication. 

A chemical Antisense Oligonucleotide (ASO) for the treatment of early Alzheimer’s disease 

Huntington’s disease is a rare, inherited and ultimately fatal neurodegenerative disease that places substantial burden on those affected and their families.  

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for around 80–85% of cases. Around 50,200 people are diagnosed with lung cancer in the UK each year. 

Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. An estimated 982,000 people were living with dementia in the UK in 2024, with the number expected to rise.  

Professor Jacob George, Chief Medical and Scientific Officer of the Medicines and Healthcare products Regulatory Agency said: 

The Innovative Licensing and Access Pathway is a globally unique initiative designed to accelerate patient access to transformative new medicines and drug-device combinations. 

This is an extract. The publication continues at the source.

Contains public sector information licensed under the Open Government Licence v3.0. Licence

Read the original at the source: https://www.gov.uk/government/news/investigational-treatments-for-lung-cancer-huntingtons-disease-and-alzheimers-gain-innovation-passports-through-the-innovative-licensing-and-access-pa

Officially imported this from Medicines and Healthcare products Regulatory Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Medicines and Healthcare products Regulatory Agency — imported from official source
Official source
https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency.atom ATOM
Imported
November 09, 2026 10:02
Versions
1 recorded
Identity
https://www.gov.uk/government/news/investigational-treatments-for-lung-cancer-huntingto...

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.